Compass Therapeutics, Inc. (CMPX) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-29

Key Insights

General Counsel Jonathan Anderman acquired 25,000 shares of common stock at $1.89 per share on 04/29/2026, increasing his direct beneficial ownership to 196,000 shares, demonstrating insider confidence in the company at current valuation levels.
The acquisition includes 150,000 unvested restricted stock units (RSUs) granted on January 2, 2026, with four-year service-based vesting and first installment vesting on January 2, 2027, indicating significant long-term incentive alignment with company performance.
The stock price of $1.89 at time of purchase suggests the company may be trading at depressed valuations, which could indicate either market weakness or a buying opportunity depending on company fundamentals and pipeline progress.

Want the newest filings?

This analysis covers the filing from 2026-04-29. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-29

Chief Accounting Officer Neil Lerner purchased 15,000 shares at $1.89 on April 29, 2026, indicating insider confidence in the company at this price point.
Lerner's total beneficial ownership reached 397,500 shares following this transaction, with 62,500 shares comprising unvested RSUs granted January 2, 2026, vesting over four years in equal annual installments.
The insider purchase represents a modest investment of approximately $28,350, which is a relatively small transaction that suggests either limited conviction or capital constraints rather than major confidence signaling.
RSU vesting schedule shows first tranche vested on January 2, 2027, indicating Lerner's compensation alignment with long-term company performance over the four-year vesting period.

Filed: 2026-02-10

The reporting person, Thomas J. Schuetz, who is the Chief Executive Officer and a Director of Compass Therapeutics, Inc. (CMPX), has disposed of 36,687 shares of the company's common stock through a tax withholding transaction.
Schuetz continues to beneficially own a significant number of shares (6,603,336) in the company, indicating his commitment and alignment with shareholders.
The transaction involves the vesting of restricted stock units (RSUs) granted to Schuetz in 2023, 2024, and 2026, which are subject to service-based vesting conditions.

Filed: 2026-01-12

The CEO of Compass Therapeutics, Inc. (CMPX) has disposed of 46,777 shares by having them withheld to cover tax withholding obligations, potentially indicating some insider selling activity.
The CEO still holds a significant number of restricted stock units (RSUs) in the company, with 250,000 RSUs granted in 2023, 318,750 RSUs granted in 2024, and 250,000 RSUs granted in 2026, suggesting a continued long-term alignment with shareholders.
The vesting schedule of the CEO's RSUs is spread out over multiple years, with the first installments vesting in 2024, 2025, and 2027, respectively, indicating a focus on long-term performance.

Filed: 2026-01-05

The CFO, Barry Shin, has acquired 125,000 shares of Compass Therapeutics, Inc. (CMPX) through restricted stock units (RSUs) on January 2, 2026, indicating insider confidence in the company's future.
Shin also holds 670,000 stock options with a strike price of $5.17, further demonstrating his alignment with shareholders' interests.
Compass Therapeutics' CFO has a significant equity stake in the company, with 525,000 shares beneficially owned, suggesting strong managerial commitment.

Filed: 2026-01-05

Jonathan Anderman, the General Counsel of Compass Therapeutics, Inc. (CMPX), acquired 150,000 restricted stock units (RSUs) and 720,000 stock options on January 2, 2026, indicating his confidence in the company's future performance.
The RSUs and options are subject to service-based vesting conditions, with the first installment of the RSUs vesting on January 2, 2027, and the options vesting over 48 substantially equal monthly installments starting February 2, 2026.
The acquisition of a significant number of equity securities by the company's General Counsel suggests positive sentiment towards the company's prospects and potential future growth.

Filed: 2026-01-05

Cynthia Sirard, the Chief Medical Officer of Compass Therapeutics, Inc., was granted 1,000,000 stock options on January 2, 2026 as a material inducement to join the company.
The stock options have an exercise price of $5.17 and will vest over a four-year period, with 25% vesting on January 2, 2027 and the remaining 75% vesting in 36 equal monthly installments.
This significant stock option grant suggests the company is placing a high value on Sirard's expertise and experience, and is incentivizing her to contribute to the company's long-term success.

Filed: 2026-01-05

The CEO, Thomas J. Schuetz, acquired 250,000 restricted stock units (RSUs) of Compass Therapeutics, Inc. on January 2, 2026, indicating his confidence in the company's future performance.
Schuetz also received a stock option grant of 2,000,000 shares with a strike price of $5.17, further aligning his interests with shareholders.
The total number of shares beneficially owned by Schuetz has increased to 6,686,800, reflecting his substantial stake in the company.

Filed: 2026-01-05

Arjun Prasad, the Chief Commercial Officer, was granted a stock option to purchase 1,000,000 shares of Compass Therapeutics' common stock at an exercise price of $5.17 per share. The options will vest over a 4-year period.
The stock option grant was made under the company's 2025 Inducement Plan, which is used to incentivize new hires as a material inducement to their employment.
This transaction indicates that Arjun Prasad, a key executive, has a vested interest in the long-term success of Compass Therapeutics and is being incentivized to drive the company's commercial growth.

Filed: 2026-01-05

The reporting person, Richard S. Lindahl, acquired 90,000 stock options to buy Compass Therapeutics, Inc. (CMPX) common stock at an exercise price of $5.17 per share. The options will vest in full on the earlier of June 10, 2026 or the date of the next annual stockholder meeting.
This insider acquisition of options suggests that Lindahl, who serves as a director of the company, is bullish on Compass Therapeutics and expects the stock price to appreciate over the long term.
The timing and size of the option grant, along with the vesting schedule, indicate that this is part of Lindahl's ongoing compensation as a director rather than a one-time transaction.

Filed: 2026-01-05

The reporting person, Ellen Chiniara, has been granted a stock option for 90,000 shares of Compass Therapeutics, Inc. (CMPX) common stock.
The stock option has an exercise price of $5.17 and vests in full upon the earlier of June 10, 2026 or the date of the next annual meeting of the company's stockholders.
This transaction indicates that Chiniara, who is a director of the company, has been awarded additional equity compensation, potentially aligning her interests with those of other shareholders.

Filed: 2026-01-05

Neil Lerner, the Chief Accounting Officer of Compass Therapeutics, Inc. (CMPX), acquired 62,500 restricted stock units (RSUs) on January 2, 2026 at $5.17 per share, indicating his alignment with the company's long-term growth.
Lerner was also granted 435,000 stock options with an exercise price of $5.17, vesting over 48 monthly installments, further suggesting his commitment to the company's success.
The acquisition of these securities suggests Lerner's confidence in Compass Therapeutics' future prospects and his willingness to invest in the company's growth.

Filed: 2026-01-05

Insider Mary Ann Gray acquired 90,000 stock options with an exercise price of $5.17, indicating potential optimism about Compass Therapeutics' future prospects.
The stock options granted to Mary Ann Gray vest fully on the earlier of June 10, 2026 or the date of the next annual stockholder meeting, suggesting the company is incentivizing long-term executive commitment.
As a director, Mary Ann Gray's insider transaction could signal confidence in Compass Therapeutics' strategic direction and future growth potential.

Filed: 2026-01-05

The reporting person, James P. Boylan, was granted 90,000 stock options on January 2, 2026 with a strike price of $5.17 and a 10-year expiration date.
The stock options will vest in full on the earlier of June 10, 2026 or the date of the next annual meeting of Compass Therapeutics, Inc. stockholders.
Pursuant to an agreement with Enavate Sciences, LP, the reporting person is obligated to transfer any securities issued under the stock options or the economic benefit thereof to Enavate.

Other reports for Compass Therapeutics, Inc.

Quarterly Report Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.